Cancer Cell Biology

癌细胞生物学

• 批准号: 7944540
• 负责人: M. LUISA IRUELA-ARISPE
• 金额: $ 5.59万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-02 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944540
• 关键词: Achievement; Animal Model; Area; Basic Science; Biological; Biological Models; Biological Sciences; Biology; Biomedical Research; Biomedical Technology; California; Cancer Biology; Cancer Center Support Grant; Cancer Detection; Cells; Cellular biology; Chemistry; Chin; Clinical; Collaborations; Communities; Complement; Comprehensive Cancer Center; Consultations; Core Facility; Critiques; Derivation procedure; Detection; Development; Developmental Biology; Developmental Cell Biology; Developmental Process; Drosophila genus; Drug Delivery Systems; Educational workshop; Emerging Technologies; Engineering; Faculty; Failure; Focus Groups; Fostering; Funding; Genetic; Genetic Screening; Gifts; Goals; Grant; Hemangioma; Hospitals; Housing; Information Dissemination; Institutes; Interest Group; Investments; Joint Ventures; Jonsson Comprehensive Cancer Center of University of California Los Angeles; Journals; Knowledge; Lead; Leadership; Lymphoma; Malignant Neoplasms; Malignant neoplasm of prostate; Mammary Neoplasms; Modeling; Molecular; Monitor; Mutation; Names; Nanotechnology; National Cancer Institute; Paper; Participant; Pathologist; Pathway interactions; Peer Review; Positioning Attribute; Preventive; Publications; Publishing; Reagent; Recruitment Activity; Refractory; Reporting; Research; Research Infrastructure; Research Personnel; Resource Sharing; Rome; Science; Scientist; Screening procedure; Seeds; Series; Signal Transduction; Stem Cell Research; Stem cells; Strategic Planning; Subgroup; The Sun; Therapeutic; Therapeutic Studies; Translations; Tumorigenicity; Universities; Ursidae Family; Work; Zebrafish; anticancer research; base; cancer cell; cancer stem cell; cancer therapy; cost; frontier; human disease; improved; innovation; insight; interest; member; metaplastic cell transformation; mouse model; nanobiology; nanosystems; neoplastic cell; outcome forecast; paracrine; pre-clinical; prognostic; programs; response; stem; stem cell biology; symposium; tumor; tumor growth; tumor progression

The CCB Program Area has 24 core members, distributed among these three focus areas. During the current funding year, peer-reviewed funding totaled $12 million in total costs, including $1.45 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CCB Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CCB Program Area total $1,042,520. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. Cancer Cell Biology Program Area members published 201 peer-reviewed papers during the recent five-year renewal period. The JCCC CCB program area is highly interactive, with 9% of its 201 publications reflecting intraprogrammatic efforts and 59% reporting inter-programmatic collaborations. 129 publications (64%) appeared in high-impact journals. The Cancer Cell Biology (CCB) Program Area was previously named the "Molecular, Cellular and Developmental Biology (MCDB) Program Area." In response to the 2002 CCSG review, and in extensive consultation with our External Advisory Board, the JCCC has reorganized this program. The goals of the reorganization were to: (1) identify critical cancer-relevant focus areas of basic science and biomedical technologies; (2) identify appropriate leaders and members for these focus areas; (3) promote intraprogrammatic interactions and collaborations within and across these groups in cancer-related areas; and (4) foster inter-programmatic interactions leading to translational and clinical collaboration. Concomitantly with the interest in reorganizing this program area, UCLA had made the strategic decision to invest heavily in infrastructure, faculty recruitment and funding in nanotechnology and stem cell biology; the California NanoSystems Institute and the Broad Stem Cell Center (BSCC) have both been created during the current JCCC CCSG funding cycle, and new buildings constructed to house these programs. The JCCC capitalized and incorporated the investment made by UCLA into our Program Area strategic plan and identified three main interest groups for the Cancer Cell Biology Program Area: (1) nanobiology applications to cancer detection, monitoring, and therapy; (2) cancer stem cell identification and eradication; and (3) model organism studies of cancer detection, progression, and therapy. Senior Associate Dean Dr. Leonard Rome, the former MCDB Program Area director, has become the JCCC Director for Strategic Planning and Partnerships. With the enthusiastic support of our EAB, Dr. Luisa Iruela-Arispe, an internationally known developmental biologist and cancer researcher has become the Director of the CCB Program Area. Dr. Michael Teitell, a pathologist and cancer biologist with strong interests in nanotechnology, brings strength in this area and a clinical perspective to the Co-Director position.

CCB计划领域有24名核心成员，分布在这三个重点领域。当前期间 资助年度，同行评审资助的总成本为 1200 万美元，其中来自国家资助的 145 万美元 癌症研究所。与其他计划领域一样，JCCC 促进了许多互动活动和许多 支持 CCB 计划领域研究人员的共享资源。在当前的拨款周期内，资金 JCCC 以 CCSG 发展基金、机构支持和慈善捐赠的形式向 CCB 计划领域总计 1,042,520 美元。这些资金支持跨学科补助金、种子补助金、 招聘/保留、计划领域领导力支持、为使用新兴共享资源提供资金 和实习生。十二个计划领域成员获得了 JCCC 的支持。癌细胞 生物学计划领域成员在最近五年更新期间发表了 201 篇同行评审论文 时期。 JCCC CCB 计划领域具有高度互动性，其 201 份出版物中有 9% 反映了计划内内容 努力，59% 报告了计划间合作。 129 篇出版物 (64%) 出现 在高影响力期刊上。 癌细胞生物学 (CCB) 计划领域以前被命名为“分子、细胞和 发育生物学 (MCDB) 计划领域。”作为对 2002 年 CCSG 审查的回应，并广泛 与我们的外部顾问委员会协商后，JCCC 重新组织了该计划。的目标 重组的目的是：（1）确定基础科学和生物医学中与癌症相关的关键重点领域 技术； (2) 为这些重点领域确定适当的领导者和成员； (3) 促进程序内化 这些群体内部和之间在癌症相关领域的互动和合作；和（4） 促进项目间互动，从而实现转化和临床合作。同时与 由于有兴趣重组该项目领域，加州大学洛杉矶分校做出了大力投资的战略决策 纳米技术和干细胞生物学的基础设施、教师招聘和资助；加利福尼亚州 纳米系统研究所和布罗德干细胞中心 (BSCC) 均是在本次会议期间创建的 JCCC CCSG 资金周期，以及为容纳这些项目而建造的新建筑。 JCCC资本化 并将加州大学洛杉矶分校的投资纳入我们的项目领域战略计划，并确定了三个主要项目 癌细胞生物学计划领域的兴趣小组：（1）纳米生物学在癌症检测中的应用， 监测和治疗； (2)癌症干细胞的识别和根除； (3) 模式生物研究 癌症检测、进展和治疗。高级副院长 Leonard Rome 博士，前 MCDB 计划领域总监，已成为 JCCC 战略规划和合作伙伴关系总监。随着 国际知名发育生物学家 Luisa Iruela-Arispe 博士对我们 EAB 的热情支持 癌症研究员成为CCB项目领域主任。 Michael Teitell 博士，病理学家 和癌症生物学家对纳米技术有浓厚的兴趣，带来了该领域的力量和临床 对联合总监职位的看法。